Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase ...

Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm.

PARIS--(BUSINESS WIRE)--Genethon, a pioneering gene therapy research organization created by AFM-Telethon, today presented positive results from the Phase 1/2 dose escalation part of an international ...

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer Data from first ...

Based on positive safety and efficacy data in the Phase 1/2 dose escalation phase of the all-in-one study, Genethon expects to launch pivotal trial in Europe in 2025 and in the US. The results showed ...

Tenaya Therapeutics, Inc., a biotechnology company focused on developing therapies for heart disease, will announce initial data from the MyPEAK-1 Phase 1b/2 clinical trial of its gene therapy TN-201 ...

Abdera Therapeutics has reported initial data from its Phase Ia study of the radiopharmaceutical biologic therapy, ABD-147, in treating individuals with small cell lung cancer (SCLC) and large cell ...

Initial Phase 1 of 2 RESET-Myositis and RESET-SLE clinical trial data of the investigational therapy, CABA-201, revealed positive outcomes. The first two study participants did not exhibit infections ...